ABOUT

Vir is a science-driven company guided by medical need.

Vir integrates diverse innovations in science, technology, and medicine to transform the care of people with serious infectious diseases. Vir is taking a multi-program, multi-platform approach to applying these breakthroughs, including the development of treatments that induce protective and therapeutic immune responses. Vir’s scale and scope, together with leading scientific and management expertise, allow it to perform significant internal R&D, in-license or acquire innovative technology platforms and assets, and fund targeted academic research.

Vir’s initial focus is in three areas of significant unmet need: chronic infectious diseases including hepatitis B, tuberculosis, and HIV; respiratory diseases, including influenza, respiratory syncytial virus (RSV), and metapneumovirus (MPV); and health-care acquired infections.

The company was founded by Robert Nelsen and ARCH Venture Partners and seeded by ARCH, the Bill & Melinda Gates Foundation, Altitude Life Sciences, and Alta Partners. Additional investors include the SoftBank Vision Fund, Temasek, Baillie Gifford, the Alaska Permanent Fund, and select sovereign wealth funds, private individuals, family offices, and other institutional investors.

Vir is headquartered in San Francisco, California with operations in Portland, Oregon, Boston, Massachusetts, and Bellinzona, Switzerland

Team

The Vir team is comprised of world leaders in immunology, infectious disease, and drug development. Learn more about our executive team, board of directors, and scientific advisors below.

Executive Team

George Scangos, Ph.D.

CEO & Director

Howard Horn

Chief Financial Officer

Michael Kamarck, Ph.D.

Chief Technology Officer 

Christian Mandl, Ph.D, M.D.

SVP, RNA Technologies

Phil Pang, M.D., Ph.D.

SVP, Clinical Development

Jay Parrish photo

Jay Parrish, Ph.D.

Chief Business Officer

Alpna Seth, Ph.D.

Chief Operating Officer 

Board of Directors

George Scangos, Ph.D.

CEO & Director

Kristina Burow

Director

Tom Daniel, M.D.

Director

Klaus Frueh, Ph.D.

Director & Co-founder

Bob More

Director

Robert Nelsen

Director & Co-founder

Deep Nishar Photo

Deep Nishar

Director

Rob Perez

Director

Scientific Advisors

Larry Corey, M.D.

Scientific Advisor & Co-founder

Jeff Bluestone, Ph.D.

Scientific Advisor

Emilio Emini, Ph.D.

Scientific Advisor

Louis Picker, M.D.

Scientific Advisor & Co-founder

Mark Davis, Ph.D

Scientific Advisor

George Poste, DVM, Ph.D.

Scientific Advisor

 

 

View All 

 

News

11/28/17
Vir Biotechnology Appoints Herbert W. “Skip” Virgin Executive Vice President and Chief Scientific Officer

SAN FRANCISCO—Vir Biotechnology, Inc. today announced the appointment of Herbert W. "Skip" Virgin, M.D., Ph.D., as Executive Vice President of Research and Chief Scientific Officer, effective January 1, 2018. Reporting to CEO George Scangos and joining Vir’s management team, Dr. Virgin will lead the company’s significant and growing R&D programs to transform the care of people with serious infectious diseases.

Read More

10/18/17
Vir Biotechnology Builds Pipeline, Capabilities, and Lays Out Strategy to Address Serious Infectious Diseases

SAN FRANCISCO—Vir Biotechnology, Inc. today announced agreements with Humabs BioMed SA, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALYN), and Visterra, Inc., as well as four leading academic research institutions. Together with the company’s internal research and development capabilities, these achievements provide the foundation on which Vir will pursue its mission of transforming the care of people with serious infectious diseases.

Read More

 

 

View All 

CAREERS at Vir Bio

View Jobs

Vir is always interested in knowing the best and the brightest talent. If you do not see a role that matches your background we encourage you to email your resume to resumes@vir.bio. This will help us find you if a new need arises that fits your experience.

Contact

VIR BIOTECHNOLOGY, INC.

San Francisco, CA
email: info@vir.bio